Deutsche Bank Aktiengesellschaft Begins Coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD)

Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report published on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $25.00 target price on the biopharmaceutical company’s stock. Several other analysts also recently issued reports on the company. JMP Securities boosted their price […]

Leave a Reply

Your email address will not be published.

Previous post Desjardins Raises Freehold Royalties (TSE:FRU) Price Target to C$19.25
Next post Wells Fargo & Company Upgrades Extra Space Storage (NYSE:EXR) to “Overweight”